Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value US$0.001 per share, offered at a price of US$28.50 per share, before underwriting discounts. The offering is expected to close on or about January 5, 2024, subject to customary closing conditions. Gross offering proceeds will be approximately US$450.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Latham & Watkins LLP represents the underwriters in the offering, with a capital markets team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associates Peter Simon, Brian Daley, and Sterling Swift.
